RESUMO
A recent history of malignancy is an absolute contraindication for lung transplantation according to the International Society of Heart and Lung Transplantation; however, a 5-year disease-free interval should be demonstrated in most cases of malignancies to consider the patient a suitable recipient. Currently, no specific guidelines are reported for addressing previous lung cancer in the selection of recipients. We report a case of a patient who underwent right upper lobectomy for small cell lung cancer in 2013 followed by adjuvant chemotherapy and prophylactic encephalic radiotherapy. In 2019 she underwent lung transplantation for emphysema. Currently she is alive with no recurrence of neoplastic disease.
Assuntos
Neoplasias Pulmonares/patologia , Transplante de Pulmão , Enfisema Pulmonar/cirurgia , Carcinoma de Pequenas Células do Pulmão/patologia , Lobectomia Temporal Anterior , Quimioterapia Adjuvante , Feminino , Humanos , Oxigenoterapia Hiperbárica , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Enfisema Pulmonar/diagnóstico , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Carcinoma de Pequenas Células do Pulmão/radioterapia , Resultado do TratamentoRESUMO
BACKGROUND: The National Comprehensive Cancer Network (NCCN) recently revised recommendations for inoperable stage I small cell lung cancer (SCLC), having added stereotactic ablative radiotherapy (SABR)/chemotherapy to the historical paradigm of concurrent conventionally-fractionated radiation therapy (CFRT)/chemotherapy. Despite the conformality, convenience, and cost-effectiveness of SABR, the NCCN continues to recommend both CFRT/chemotherapy and SABR/chemotherapy primarily because these approaches have not been comparatively analyzed to date. METHODS: The National Cancer Database was queried for histologically-confirmed T1-2N0M0 SCLC; all patients received chemotherapy. Multivariable logistic regression ascertained factors associated with SABR/chemotherapy. Kaplan-Meier analysis assessed overall survival (OS); multivariable Cox proportional hazards modeling examined factors associated with OS. Survival was also calculated following propensity matching. RESULTS: Of 2,107 patients, 7.1% underwent SABR/chemotherapy, and 92.9% received CFRT/chemotherapy. The median (interquartile range) dose of SABR was 50 (48-54) Gy in 4 (3-5) fractions, and 55.8 (45-60) Gy in 30 (30-33) fractions for CFRT. Patients receiving SABR/chemotherapy were more often older, had T1 disease, treated at academic/integrated network facilities, and managed in more recent years (pâ¯<â¯0.05 for all). Respective median survival figures were 29.2 versus 31.2â¯months (pâ¯=â¯0.77), which persisted following propensity matching (25.4 versus 34.3â¯months, pâ¯=â¯0.85). On multivariable analysis, radiotherapeutic technique was not associated with OS (pâ¯=â¯0.95). CONCLUSIONS: For stage I SCLC, SABR/chemotherapy affords statistically equivalent outcomes to CFRT/chemotherapy. Because randomized studies addressing this uncommon scenario would almost certainly suffer from inadequate accrual, these retrospective data should be strongly considered in efforts to institute SABR/chemotherapy as the preferred option for this population.
Assuntos
Técnicas de Ablação/métodos , Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/cirurgia , Radiocirurgia/métodos , Carcinoma de Pequenas Células do Pulmão/radioterapia , Carcinoma de Pequenas Células do Pulmão/cirurgia , Idoso , Quimiorradioterapia , Bases de Dados Factuais , Fracionamento da Dose de Radiação , Feminino , Humanos , Estimativa de Kaplan-Meier , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Estadiamento de Neoplasias , Estudos Retrospectivos , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Carcinoma de Pequenas Células do Pulmão/patologiaRESUMO
BACKGROUND: Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy delivered once daily (QD). However, the current practice patterns among US radiation oncologists are unknown. MATERIALS AND METHODS: We surveyed US radiation oncologists using an institutional review board-approved questionnaire. The questions covered demographic data, self-rated knowledge of key trials, and treatment recommendations. RESULTS: We received 309 responses from radiation oncologists. Of the 309 radiation oncologists, 60% preferred TRT QD and 76% acknowledged QD to be more common in their practice. The respondents in academic settings were more likely to endorse BID treatment by both preference (P = .001) and actual practice (P = .009). The concordance between preferring QD and administering QD in practice was 100%. In contrast, 40% of respondents who preferred BID actually administered QD more often. Also, 15% of physicians would be unwilling to switch from QD to BID and 3% would be unwilling to switch from BID to QD, even on patient request. Most respondents (88%) recommended a dose of 45 Gy for BID treatment. For QD treatment, the division was greater, with 54% recommending 60 Gy, 30% recommending 63 to 66 Gy, and 10% recommending 70 Gy. CONCLUSION: Substantial variation exists in how US radiation oncologists approach TRT dosing and fractionation for LS-SCLC. Three quarters of our respondents reported administering TRT QD most often. The most common doses were 60 Gy QD and 45 Gy BID. The results of the present survey have provided the most up-to-date information on US practice patterns for LS-SCLC.
Assuntos
Neoplasias Pulmonares/radioterapia , Radio-Oncologistas , Carcinoma de Pequenas Células do Pulmão/radioterapia , Fracionamento da Dose de Radiação , Feminino , Humanos , Neoplasias Pulmonares/epidemiologia , Masculino , Estadiamento de Neoplasias , Padrões de Prática Médica , Dosagem Radioterapêutica , Carcinoma de Pequenas Células do Pulmão/epidemiologia , Inquéritos e Questionários , Estados Unidos/epidemiologiaRESUMO
INTRODUCTION: Numbers of prognostic factors of small cell lung cancer (SCLC) have been demonstrated in previous studies. However, the identification of biomarkers with easy access, convenience, and low consumption is of great value in clinics. OBJECTIVES: In order to find such a biomarker, a single institution study with 1156 SCLC patients was retrospectively conducted to assess the prognostic value of prognostic nutritional index (PNI) on SCLC patients treated with platinum-based chemotherapy. METHODS: The optimal cut-off values were determined by a receiver operating characteristic (ROC) curve analysis. Univariate and multivariate analyses were used to assess their prognostic values for overall survival (OS). RESULTS: On univariate analysis, age, smoking history, tumor stage, PNI, radiotherapy, and surgery were significantly associated with OS. Age, stage, PNI, radiotherapy, and surgery held statistical significance on multivariate analysis. High PNI was closely associated with younger age, limited disease, and radiotherapy. PNI was also demonstrated to be an independent prognostic factor in subgroups analysis, especially in patients with age ≤ 60, no smoking history, no family history of tumor, and no radiotherapy. CONCLUSIONS: Age ≤ 60 years, limited disease, high PNI, radiotherapy, and surgery were independent positive prognostic factors of SCLC patients treated with chemotherapy. PNI was a good biomarker for the assessment of SCLC prognosis for its easy access, convenience to be calculated, and low consumption. Pretreatment PNI can better predict the prognosis of SCLC, especially in patients with age ≤ 60, no smoking history, no family history of tumor, and no radiotherapy.
Assuntos
Tratamento Farmacológico/métodos , Neoplasias Pulmonares/mortalidade , Avaliação Nutricional , Platina/uso terapêutico , Carcinoma de Pequenas Células do Pulmão/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/cirurgia , Masculino , Pessoa de Meia-Idade , Platina/administração & dosagem , Prognóstico , Estudos Retrospectivos , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Carcinoma de Pequenas Células do Pulmão/radioterapia , Carcinoma de Pequenas Células do Pulmão/cirurgiaRESUMO
PURPOSE: The role of prophylactic cranial irradiation (PCI) remains controversial in extensive stage small cell lung cancer (ES-SCLC) with the publication of 2 randomized control trials demonstrating differing outcomes in overall survival. The aim of this study is to determine the impact of PCI on survival and the development of brain metastasis while addressing the disparate use of postchemotherapy brain imaging in the aforementioned trials. METHODS AND MATERIALS: The medical records of 397 consecutive patients with ES-SCLC between Jan. 1, 2005 and Dec. 31, 2011 were retrospectively reviewed. In those eligible patients (n = 155) without baseline brain metastases and who had at least a partial response to chemotherapy, overall survival and time to brain metastasis were estimated using the Kaplan-Meier method comparing patients receiving PCI or not, using both univariate and multivariate analyses. Patients were stratified by their receipt of initial postchemotherapy brain imaging. Follow-up did not include serial brain imaging, which was performed when clinically indicated. Differences between the groups with covariates were analyzed using χ2 statistics and Student's t-tests. RESULTS: By multivariate analysis, statistically significant predictors of overall survival were the presence of extrathoracic metastases, performance status and use of PCI. There was a statistically significant difference in overall survival (HR 0.55; 95% CI: 0.39-0.77; P = .0005) and time to brain metastasis (HR 0.40; 95% CI: 0.23-0.66; P = .0004) with the use of PCI. Median survival for the PCI and non-PCI groups was 13.5 and 8.5 months respectively. A survival difference with PCI was observed in both patients that received postchemotherapy brain imaging (HR 0.55; 95% CI: 0.35-0.88; P = .012) and those who did not (HR 0.48; 95% CI: 0.29-0.77; P = .0025). CONCLUSIONS: PCI in the setting of at least a partial response to chemotherapy was found to have a survival benefit and prolongation of the time to development of brain metastases, when factoring in the use of initial postchemotherapy but not routine surveillance brain imaging.
Assuntos
Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/secundário , Encéfalo/efeitos da radiação , Irradiação Craniana/métodos , Neoplasias Pulmonares/patologia , Carcinoma de Pequenas Células do Pulmão/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias Encefálicas/mortalidade , Institutos de Câncer , Tratamento Farmacológico , Feminino , Humanos , Estimativa de Kaplan-Meier , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/radioterapia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Metástase Neoplásica , Estudos Retrospectivos , Carcinoma de Pequenas Células do Pulmão/mortalidade , Carcinoma de Pequenas Células do Pulmão/radioterapia , Resultado do TratamentoRESUMO
PURPOSE: Prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (LS-SCLC) is considered the standard of care. Meta-analysis of 7 clinical trials indicates a survival benefit to PCI, but all of these trials were conducted in the pre-magnetic resonance imaging (MRI) era. Therefore, routine brain imaging with MRI before PCI-as recommended by National Comprehensive Cancer Network guidelines-is not directly supported by the evidence. Current US practice patterns for patients with LS-SCLC are unknown. MATERIALS AND METHODS: We surveyed practicing US radiation oncologists via an institutional review board-approved online questionnaire. Questions covered demographic information and treatment recommendations for LS-SCLC. RESULTS: We received 309 responses from US radiation oncologists. Ninety-eight percent recommended PCI for patients with LS-SCLC, 96% obtained brain MRI before PCI, 33% obtained serial brain imaging with MRI after PCI to detect new metastases, and 35% recommended memantine for patients undergoing PCI. Recommending memantine was associated with fewer years of practice (P < .001), fewer lung cancer patients treated per year (P = .045), and fewer LS-SCLC patients treated per year (P = .024). CONCLUSION: Almost all responding radiation oncologists recommended PCI and pre-PCI brain MRI for LS-SCLC patients with disease responsive to initial therapy. Only a third of respondents followed these patients with serial brain MRI. Approximately one third provided memantine therapy to try to limit neurocognitive effects of PCI. Further research is warranted to determine the best treatment for patients with LS-SCLC. This survey can inform the development of future trials that depend on participation from radiation oncologists.
Assuntos
Neoplasias Encefálicas/prevenção & controle , Neoplasias Encefálicas/secundário , Irradiação Craniana , Padrões de Prática Médica , Carcinoma de Pequenas Células do Pulmão/secundário , Encéfalo/efeitos da radiação , Transtornos Cognitivos/etiologia , Transtornos Cognitivos/prevenção & controle , Irradiação Craniana/efeitos adversos , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/radioterapia , Memantina/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Radio-Oncologistas , Radioterapia (Especialidade) , Carcinoma de Pequenas Células do Pulmão/radioterapia , Inquéritos e QuestionáriosRESUMO
PURPOSE: Despite the recent CREST trial demonstrating a survival benefit to thoracic radiotherapy (TRT) for patients with extensive-stage small-cell lung cancer (ES-SCLC) with response to chemotherapy, as well as endorsement by current National Comprehensive Cancer Network guidelines, TRT may not be uniformly delivered in clinical practice across all circumstances. METHODS AND MATERIALS: We surveyed US academic thoracic radiation oncologists regarding their practice patterns for TRT and assessed conditions in which withholding TRT could be warranted. A 27-question survey of demographics and practice patterns, including 5 clinical cases, was sent to 111 physicians. RESULTS: Response rate was 39% (43/111). Among respondents, 60% have at least 6 years of work experience following residency; 77% and 71% respectively see > 50 lung cancer and > 11 SCLC cases annually. Regarding practice patterns, 74% use TRT in 26% to 75% of patients with ES-SCLC. Respondents would withhold TRT in cases with Eastern Cooperative Oncology Group performance status ≥ 3 (91%), when pulmonary function necessitates continuous oxygen via nasal cannula (62%), for postchemotherapy tumor progression (58%), and if > 4 postchemotherapy extrathoracic metastases were present (58%). The 5 clinical cases highlighted practice variability, although 1 case had 100% agreement among respondents. CONCLUSIONS: Despite support of TRT administration from the CREST trial, there are several conditions associated with frequently withholding TRT. The most common reasons include performance status, postchemotherapy extent of disease, and pulmonary function; age and prechemotherapy extent of disease were least associated. Further research should aim to identify which subgroups of ES-SCLC benefit most from TRT.
Assuntos
Neoplasias Pulmonares/epidemiologia , Oncologistas , Padrões de Prática Médica/estatística & dados numéricos , Carcinoma de Pequenas Células do Pulmão/epidemiologia , Tórax/efeitos da radiação , Centros Médicos Acadêmicos , Adulto , Competência Clínica , Feminino , Humanos , Avaliação de Estado de Karnofsky , Neoplasias Pulmonares/radioterapia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Testes de Função Respiratória , Carcinoma de Pequenas Células do Pulmão/radioterapia , Inquéritos e Questionários , Tórax/patologia , Estados Unidos/epidemiologia , Suspensão de TratamentoRESUMO
OBJECTIVES: Current National Comprehensive Cancer Network (NCCN) guidelines recommend thoracic consolidation radiation therapy (TCRT) for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) with response to systemic chemotherapy, based on two randomized clinical trials, which varied in patient selection and radiation therapy doses administered. The current pattern of practice among US radiation oncologists is unknown. MATERIALS AND METHODS: We have surveyed practicing US radiation oncologist via a short online questionnaire. Respondents' characteristics and their self-rated knowledge base were analyzed for association with their treatment recommendations. RESULTS: We received 473 responses from practicing US radiation oncologists. Over half of respondents were practicing for over 10 years after completing residency training and 70% treated more than 10 lung cancer patients per year. 96% of respondents recommend TCRT for patients with ES-SCLC after systemic chemotherapy. Patient selection and radiation therapy doses vary greatly. High self-rated knowledge of individual clinical trials is associated with lower TCRT recommended doses. Patients treated at academic centers are less likely to receive TCRT than patients treated in private clinics (p=0.0101). CONCLUSION: Our analysis revealed that among the respondents, there was a very high adherence to current NCCN guidelines, which recommend TCRT for ES-SCLC patients with clinical response to systemic chemotherapy. The great variability in patient selection and radiation therapy doses is concerning and calls for future clinical trials to standardize treatment approaches and improve treatment outcomes among patients with ES-SCLC. Until such data exists and in light of poor long-term survival of patients with ES-SCLC, the shorter and less toxic regimen of 30Gy in 10 fractions should be used as the standard of care and the more aggressive regimens studied on clinical protocols.
Assuntos
Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Oncologistas/estatística & dados numéricos , Radioterapia/métodos , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Carcinoma de Pequenas Células do Pulmão/radioterapia , Terapia Combinada/métodos , Fidelidade a Diretrizes , Humanos , Neoplasias Pulmonares/patologia , Seleção de Pacientes , Padrões de Prática Médica/tendências , Radioterapia/normas , Carcinoma de Pequenas Células do Pulmão/patologia , Inquéritos e Questionários , Resultado do Tratamento , Estados UnidosRESUMO
INTRODUCTION: Conflicting data from randomized clinical trials incite the debate over the appropriate use of prophylactic cranial irradiation (PCI) for patients with extensive-stage SCLC (ES-SCLC) who achieve clinical response to systemic chemotherapy. The current pattern of practice among U.S. radiation oncologists is unknown. METHODS: We surveyed practicing U.S. radiation oncologists through a short online questionnaire. Respondents' characteristics and their self-rated knowledge base were analyzed for association with their treatment recommendations. RESULTS: We received 473 responses from practicing U.S. radiation oncologists. More than half of the respondents had been practicing for more than 10 years after completing residency training, and 70% had treated more than 10 patients with lung cancer per year. Of the respondents, 90% recommended brain magnetic resonance imaging (MRI) before initiation of PCI and 98% recommended PCI for patients with ES-SCLC after systemic chemotherapy. Half of the respondents followed their patients with brain MRI after completion of PCI. One-third of the respondents prescribed memantine to patients undergoing PCI. Among the respondents, recent graduates (p = 0.004) and physicians practicing in academic centers (p = 0.005) were more likely to prescribe memantine. Self-rated knowledge base was not associated with any treatment recommendations. CONCLUSIONS: Our analysis revealed that among the respondents, there was a very high adherence to current National Comprehensive Cancer Network guidelines, which recommend providing universal PCI and obtaining brain MRI before initiation of PCI for patients with ES-SCLC with clinical response to systemic chemotherapy. These guidelines and practice patterns are not supported by clinical evidence because patients in the European Organization for Research and Treatment of Cancer trial did not undergo brain MRI before PCI and the Japanese randomized trial has shown a possible detrimental effect of PCI on overall survival when brain MRI was incorporated. A critical reevaluation of current guidelines is essential to determine the appropriate management of these patients.